tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NBIX Stock Latest News

Neurocrine price target raised to $149 from $144 at RBC Capital
The FlyNeurocrine price target raised to $149 from $144 at RBC Capital
2d ago
NBIX
Neurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating
PremiumRatings
Neurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating
24d ago
NBIX
Promising Growth and Strategic Positioning Drive Buy Rating for Neurocrine
PremiumRatings
Promising Growth and Strategic Positioning Drive Buy Rating for Neurocrine
1M ago
NBIX
Neurocrine Biosciences Advances Schizophrenia Treatment with Phase 3 Study
PremiumCompany Announcements
Neurocrine Biosciences Advances Schizophrenia Treatment with Phase 3 Study
1M ago
NBIX
Neurocrine Biosciences Advances Phase 3 Study on Valbenazine for Cerebral Palsy Dyskinesia
PremiumCompany Announcements
Neurocrine Biosciences Advances Phase 3 Study on Valbenazine for Cerebral Palsy Dyskinesia
1M ago
NBIX
Neurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors
PremiumCompany AnnouncementsNeurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors
1M ago
NBIX
Neurocrine’s Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating
Premium
Ratings
Neurocrine’s Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating
1M ago
NBIX
Neurocrine price target raised to $175 from $165 at Guggenheim
Premium
The Fly
Neurocrine price target raised to $175 from $165 at Guggenheim
1M ago
NBIX
Neurocrine Biosciences’ Earnings Call Highlights Growth
PremiumCompany Announcements
Neurocrine Biosciences’ Earnings Call Highlights Growth
1M ago
NBIX
Neurocrine price target raised to $175 from $154 at Piper Sandler
PremiumThe Fly
Neurocrine price target raised to $175 from $154 at Piper Sandler
1M ago
NBIX
Neurocrine price target raised to $186 from $180 at Baird
PremiumThe Fly
Neurocrine price target raised to $186 from $180 at Baird
1M ago
NBIX
Neurocrine price target raised to $170 from $165 at TD Cowen
PremiumThe Fly
Neurocrine price target raised to $170 from $165 at TD Cowen
1M ago
NBIX
Neurocrine price target raised to $170 from $165 at TD Cowen
PremiumThe FlyNeurocrine price target raised to $170 from $165 at TD Cowen
1M ago
NBIX
Neurocrine price target raised to $141 from $137 at Wedbush
Premium
The Fly
Neurocrine price target raised to $141 from $137 at Wedbush
1M ago
NBIX
Buy Rating for Neurocrine’s Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment
Premium
Ratings
Buy Rating for Neurocrine’s Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment
1M ago
NBIX
Neurocrine price target raised to $145 from $140 at JPMorgan
PremiumThe Fly
Neurocrine price target raised to $145 from $140 at JPMorgan
1M ago
NBIX
Neurocrine’s Strong Financial Performance and Growth Prospects Drive Buy Rating
PremiumRatings
Neurocrine’s Strong Financial Performance and Growth Prospects Drive Buy Rating
1M ago
NBIX
Neurocrine’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Commercial Execution and Growth Opportunities
PremiumRatings
Neurocrine’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Commercial Execution and Growth Opportunities
1M ago
NBIX
Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy Rating
PremiumRatings
Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy Rating
1M ago
NBIX
Neurocrine Biosciences Reports Strong Q2 2025 Growth
PremiumCompany AnnouncementsNeurocrine Biosciences Reports Strong Q2 2025 Growth
1M ago
NBIX
Neurocrine’s Strong Growth Potential and Positive Outlook Justify Buy Rating
Premium
Ratings
Neurocrine’s Strong Growth Potential and Positive Outlook Justify Buy Rating
1M ago
NBIX
Neurocrine narrows FY25 Ingrezza net product sales view to $2.50B-$2.55B
Premium
The Fly
Neurocrine narrows FY25 Ingrezza net product sales view to $2.50B-$2.55B
1M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >